Literature DB >> 16604553

Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?

Robert T Pu1, Jack Yang, Patricia G Wasserman, Tawfiqul Bhuiya, Kent A Griffith, Claire W Michael.   

Abstract

Thyroid fine-needle aspiration (FNA) is a standard procedure for the clinical triage of thyroid nodules. The diagnosis of an adequately sampled thyroid FNA is generally grouped into three categories: benign, malignant, and indeterminate. The latter group usually includes follicular neoplasm, follicular lesion, and sometimes a more specific diagnosis such as Hurthle cell neoplasm or follicular lesion/neoplasm with Hurthle cell change. Whether a FNA diagnosis of Hurthle cell lesion/neoplasm (HLN) denotes a worse clinical outcome than follicular lesion/neoplasm (FLN) remains controversial. A cohort of 303 thyroid FNA cases with follow-up thyroidectomy in our institutes was identified, with the follow-up excision diagnosis compared to the FNA diagnosis in order to address this issue. Of this cohort, 87 cases had an FNA diagnosis of HLN while 216 cases had a diagnosis of FLN. Upon excision, the FNA diagnosis of HLN group had 14 cases of goiter/nodular hyperplasia (16%), 46 cases of adenoma (12 follicular adenoma (14%) and 34 cases of Hurthle cell adenoma (39%)), and 27 cases of carcinoma (31%, 12 papillary carcinoma and 15 Hurthle cell carcinoma). The FLN group had 74 cases of goiter/nodular hyperplasia (34.3%), 8 cases of Hashimoto thyroiditis (3.7%), 73 cases of follicular adenoma (33.8%), one case of granular cell tumor, and 60 cases of carcinoma (27.8%, 46 papillary carcinoma, 12 follicular carcinoma, and 1 Hurthle cell carcinoma and 1 parathyroid carcinoma) upon excision. There is no significant difference in predicting cancer between the two cytology diagnosis groups (HLN versus FLN, 31% versus 27.8%, P = 0.5771). When sorting all the cases by the surgical diagnosis, while comparable for age at diagnosis, the cancer group having the higher proportion of male patients than the non-cancer group (28.7% versus 16.7%, P = 0.0259). Hurthle cell carcinoma patients are typically older than patients with other cancer diagnoses (59 versus 44, P = 0.0077). Our results suggest that an FNA diagnosis of HLN does not predict more malignancy than FLN. Males and older patients with a HLN FNA diagnosis carry a higher risk of Hurthle cell carcinoma upon thyroidectomy.

Entities:  

Mesh:

Year:  2006        PMID: 16604553     DOI: 10.1002/dc.20440

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  23 in total

1.  Search for genetic mutations in cytological samples from thyroid nodules as a diagnostic tool: reality, hope or myth?

Authors:  F Pacini; S Cantara; M Capezzone
Journal:  J Endocrinol Invest       Date:  2010-09       Impact factor: 4.256

Review 2.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

3.  The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.

Authors:  Yin Ren; Natalia Kyriazidis; William C Faquin; Selen Soylu; Dipti Kamani; Rayan Saade; Nicole Torchia; Carrie Lubitz; Louise Davies; Nikolaos Stathatos; Antonia E Stephen; Gregory W Randolph
Journal:  Thyroid       Date:  2020-03       Impact factor: 6.568

4.  Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance.

Authors:  Courtney J Balentine; David J Vanness; David F Schneider
Journal:  Surgery       Date:  2017-11-08       Impact factor: 3.982

5.  Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.

Authors:  Peter M Sadow; Michael C Heinrich; Christopher L Corless; Jonathan A Fletcher; Vânia Nosé
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

Review 6.  Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis.

Authors:  Pierpaolo Trimboli; Giorgio Treglia; Leo Guidobaldi; Enrico Saggiorato; Giuseppe Nigri; Anna Crescenzi; Francesco Romanelli; Fabio Orlandi; Stefano Valabrega; Ramin Sadeghi; Luca Giovanella
Journal:  Endocrine       Date:  2013-10-03       Impact factor: 3.633

7.  The frequency of malignancy and the relationship between malignancy and ultrasonographic features of thyroid nodules with indeterminate cytology.

Authors:  Yasemin Tutuncu; Dilek Berker; Serhat Isik; Gulhan Akbaba; Ufuk Ozuguz; Ferit Kerim Kucukler; Erdal Göcmen; Yavuz Yalcın; Yusuf Aydin; Serdar Guler
Journal:  Endocrine       Date:  2013-03-17       Impact factor: 3.633

8.  Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid.

Authors:  Rebecca S Sippel; Dina M Elaraj; Elham Khanafshar; Rasa Zarnegar; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

9.  Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcomes.

Authors:  Adolfo Pisanu; Barbara Di Chiara; Isabella Reccia; Alessandro Uccheddu
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

10.  Malignancy risk for solitary and multiple nodules in Hürthle cell-predominant thyroid fine-needle aspirations: A multi-institutional study.

Authors:  Kristine S Wong; Vickie Y Jo; Alarice C Lowe; William C Faquin; Andrew A Renshaw; Akeesha A Shah; Michael H Roh; Edward B Stelow; Jeffrey F Krane
Journal:  Cancer Cytopathol       Date:  2019-11-21       Impact factor: 5.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.